The FDA has accepted for review the BLA for lerodalcibep to reduce LDL-C in patients with or high risk of ASCVD and primary hyperlipidemia.

The Trump Administration’s censorship extends beyond federal websites and datasets to include research to be published in academic journals.

The rescheduling of marijuana may remove regulatory hurdles and expand the breadth of research beyond pain management.

Artificial intelligence (AI) can improve detection of congenital heart defects (CHDs) on routine prenatal ultrasounds.

A study has found that, among women with breast cancer, aerobic exercise significantly decreases risk for cardiovascular disease.

The FDA has issued a safety communication regarding the potential for missed alerts with diabetes devices due to software or hardware changes.

Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke.

TAT and several other markers demonstrated an ability to predict the development of venous thromboembolism in patients with cervical cancer.

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...

Patients that receive virtual cardiac rehabilitation have improved hospital admission and emergency department visit rates.